A RANDOMIZED, MULTICENTER STUDY OF FIRST-LINE AMBRISENTAN AND TADALAFIL COMBINATION THERAPY IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION PROTOCOL NUMBER: GS-US-300-0140

Approval Date: 3/13/2012

Principal Investigator: Samuel Allen, DO

Eligibility:

For more information visit

http://clinicaltrials.gov/ct2/show/NCT01178073 [1]

Contact Person:
Coleen Tessmar, Research Coordinator
248-964-8524

Status of Clinical Trial:
open and enrolling